Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 | P17948 | 1/20 | 0.41 |
| ▸ | FLT4 | P35916 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 8/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | TMPRSS4 | Q9NRS4 | 2/20 | 0.36 |
| ▸ | MGAM | O43451 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SI | P14410 | 1/20 | 0.35 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20360448 | 1.00 | FLT1 (0.41) | FLT1FLT4KDRGRIK1TSHR | |
| SCHEMBL612265 | 0.78 | FLT1 (0.46) | FLT1FLT4KDRGRIK1TSHR | |
| SCHEMBL31678938 | 0.78 | FLT1 (0.46) | FLT1FLT4KDRGRIK1TSHR | |
| SCHEMBL12685611 | 0.75 | ALDH1A1 (0.48) | TSHRALDH1A1MAPTGAAMEN1 | |
| SCHEMBL395189 | 0.74 | SMN1; SMN2 (0.63) | FLT1FLT4KDRGRIK1TSHR | |
| SCHEMBL3312420 | 0.72 | FLT1 (0.44) | FLT1FLT4KDRGRIK1TSHR | |
| SCHEMBL3312429 | 0.72 | FLT1 (0.44) | FLT1FLT4KDRGRIK1TSHR | |
| SCHEMBL3312425 | 0.72 | FLT1 (0.44) | FLT1FLT4KDRGRIK1TSHR | |
| SCHEMBL20360438 | 0.72 | FLT1 (0.44) | FLT1FLT4KDRGRIK1SMN1; SMN2 | |
| SCHEMBL20360313 | 0.71 | FLT1 (0.46) | FLT1FLT4KDRGRIK1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282748-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2025-09-11 | — | — | US | disclosed |
| US-20230024752-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-01-26 | — | — | US | disclosed |
| US-20230024752-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-01-26 | — | — | US | disclosed |
| US-11180471-B2 | Substituted oxopyridine derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-11-23 | — | — | US | disclosed |
| US-11180471-B2 | Substituted oxopyridine derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-11-23 | — | — | US | disclosed |
| EP-3319956-B1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | Bayer Pharma AG (DE) | 2021-01-06 | — | — | EP | disclosed |
| EP-3319956-B1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | Bayer Pharma AG (DE) | 2021-01-06 | — | — | EP | disclosed |
| US-10421742-B2 | Substituted oxopyridine derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-09-24 | — | — | US | disclosed |
| US-10421742-B2 | Substituted oxopyridine derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-09-24 | — | — | US | disclosed |
| US-20180194745-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-07-12 | — | — | US | disclosed |
| US-20180194745-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-07-12 | — | — | US | disclosed |
| US-20180194745-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10421742-B2 | Substituted oxopyridine derivatives | OGFOD1, VASP, PNPO | FLT1 103/4885FLT4 104/4885KDR 79/4885 |
| US-11180471-B2 | Substituted oxopyridine derivatives | OGFOD1, VASP, PNPO | FLT1 103/4885FLT4 104/4885KDR 79/4885 |
| US-20180194745-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | OGFOD1, VASP, PNPO | FLT1 103/4885FLT4 104/4885KDR 79/4885 |
| US-20250282748-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | OGFOD1, VASP, PNPO | FLT1 103/4885FLT4 104/4885KDR 79/4885 |
| US-20230024752-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | OGFOD1, VASP, PNPO | FLT1 103/4885FLT4 104/4885KDR 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.